In low-grade gliomas, isocitrate dehydrogenase (IDH) mutations were found with higher frequencies (83%), compared to grade III astrocytoma (70%) or primary and recurrent GBM (5%) (3). The gene discussed is IDH2; the disease is central nervous system cancer.